Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.

[1]  Darrell J Irvine,et al.  Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers , 2019, Science.

[2]  S. Buus,et al.  Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA , 2018, Molecular therapy. Methods & clinical development.

[3]  Dong Soo Yun,et al.  Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes , 2018, Scientific Reports.

[4]  F. Alt,et al.  Glycan Masking Focuses Immune Responses to the HIV‐1 CD4‐Binding Site and Enhances Elicitation of VRC01‐Class Precursor Antibodies , 2018, Immunity.

[5]  D. Weissman,et al.  Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses , 2018, The Journal of experimental medicine.

[6]  Daniel W. Kulp,et al.  Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline‐Targeting HIV Vaccine Immunogens , 2018, Immunity.

[7]  U. Şahin,et al.  Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Yuhua Wang,et al.  mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  T. Kepler,et al.  Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations , 2017, Nature Communications.

[10]  A. Fauci.  An HIV Vaccine Is Essential for Ending the HIV/AIDS Pandemic. , 2017, JAMA.

[11]  R. Gottardo,et al.  Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial , 2017, The Lancet.

[12]  Kimberly J. Hassett,et al.  Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  S. Crotty,et al.  Germinal center enhancement by extended antigen availability. , 2017, Current opinion in immunology.

[14]  Daniel W. Kulp,et al.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.

[15]  Kimberly J. Hassett,et al.  Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Justin M. Richner,et al.  Modified mRNA Vaccines Protect against Zika Virus Infection , 2017, Cell.

[17]  B. Haynes,et al.  Developing an HIV vaccine , 2017, Science.

[18]  D. Weissman,et al.  Zika virus protection by a single low dose nucleoside modified mRNA vaccination , 2017, Nature.

[19]  B. Haynes,et al.  The quest for an antibody‐based HIV vaccine , 2017, Immunological reviews.

[20]  L. Stamatatos,et al.  Germline‐targeting immunogens , 2017, Immunological reviews.

[21]  G. Vanham,et al.  Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Daniel G. Anderson,et al.  Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination , 2016, Proceedings of the National Academy of Sciences.

[23]  Daniel W. Kulp,et al.  Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice , 2016, Science.

[24]  Daniel W. Kulp,et al.  Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice , 2016, Cell.

[25]  F. Alt,et al.  Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires , 2016, Cell.

[26]  David Nemazee,et al.  Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies , 2016, Cell.

[27]  Dong Soo Yun,et al.  HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies , 2016, Immunity.

[28]  M. Fotin‐Mleczek,et al.  Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. , 2016, Vaccine.

[29]  N. Petrovsky,et al.  Molecular mechanisms for enhanced DNA vaccine immunogenicity , 2016, Expert review of vaccines.

[30]  John P. Moore,et al.  HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. , 2016, Trends in immunology.

[31]  R. Roden,et al.  Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease , 2016, Cell & Bioscience.

[32]  A. Bolhassani,et al.  Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. , 2016, Vaccine.

[33]  R. Weiss,et al.  N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[34]  V. Volchkova,et al.  A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates. , 2015, The Journal of infectious diseases.

[35]  John P. Moore,et al.  Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.

[36]  Ron Weiss,et al.  Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery , 2015 .

[37]  Ron Weiss,et al.  Mammalian synthetic circuits with RNA binding proteins delivered by RNA , 2015, Nature Biotechnology.

[38]  David Nemazee,et al.  Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen , 2015, Science.

[39]  Daniel W. Kulp,et al.  Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice , 2015, Cell.

[40]  John R Mascola,et al.  Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.

[41]  H. Liao,et al.  Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. , 2015, The Journal of infectious diseases.

[42]  J. Ulmer,et al.  Vaccines ‘on demand’: science fiction or a future reality , 2015, Expert opinion on drug discovery.

[43]  K. Ljungberg,et al.  Self-replicating alphavirus RNA vaccines , 2015, Expert review of vaccines.

[44]  M. Nussenzweig,et al.  Immunology: Fifty years of B lymphocytes , 2015, Nature.

[45]  C. Mandl,et al.  A cationic nanoemulsion for the delivery of next-generation RNA vaccines. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  K. Ljungberg,et al.  Kinetic and Phenotypic Analysis of CD8+ T Cell Responses after Priming with Alphavirus Replicons and Homologous or Heterologous Booster Immunizations , 2014, Journal of Virology.

[47]  D. Beasley,et al.  Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs , 2014, Proceedings of the National Academy of Sciences.

[48]  Wei Zhang,et al.  Enhancement of Antitumor Immunity Using a DNA-Based Replicon Vaccine Derived from Semliki Forest Virus , 2014, PloS one.

[49]  D. Meruelo,et al.  Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  Daphne Koller,et al.  The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies , 2013, PLoS pathogens.

[51]  Donald K Carter,et al.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. , 2013, The Journal of infectious diseases.

[52]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[53]  L. Stamatatos,et al.  Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.

[54]  L. Stamatatos,et al.  Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs , 2013, PLoS pathogens.

[55]  N. Sardesai,et al.  Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses , 2012, Science Translational Medicine.

[56]  Thomas Krucker,et al.  Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.

[57]  C. Mandl,et al.  RNA-based vaccines. , 2012, Vaccine.

[58]  W. Blattner,et al.  Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults , 2012, PloS one.

[59]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[60]  D. Weissman,et al.  Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA , 2011, Nucleic acids research.

[61]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[62]  S. Quezada,et al.  Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). , 2010, Current opinion in immunology.

[63]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  J. Mascola,et al.  Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. , 2006, Virology.

[65]  R. Gorchakov,et al.  Noncytopathic Replication of Venezuelan Equine Encephalitis Virus and Eastern Equine Encephalitis Virus Replicons in Mammalian Cells , 2005, Journal of Virology.

[66]  L. Jeffs,et al.  A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA , 2005, Pharmaceutical Research.

[67]  S. Pascolo.  Messenger RNA-based vaccines , 2004, Expert opinion on biological therapy.

[68]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.